SEMAGLUTIDE



NAME OF DRUG : SEMAGLUTIDE

LABORATORY : NOVONORDISK

STATUS AND ADVANCEMENT

Type of drug : GLP_1analog

Clinical trials advancement : Recruiting Phase 2b

Estimated time to market : 103 months.

LABORATORY ABSTRACT ON THE DRUG

Semaglutide is a once-weekly investigational analogue of human glucagon-like peptide-1 (GLP-1) that stimulates insulin and suppresses glucagon secretion in a glucose- dependent manner, while decreasing appetite and food intake.3 With SUSTAIN 6, semaglutide, administered subcutaneously once-weekly, has completed six phase 3a clinical trials for the treatment of adults with type 2 diabetes.

RECENT NEWS ON SEMAGLUTIDE

2017-08-19 : SEMAGLUTIDE PERSPECTIVES IN NASH

SOME PUBLICATIONS RELATED WITH SEMAGLUTIDE

August 2017 : Glucagon-like peptide-1 analogues in nonalcoholic steatohepatitis: From bench to bedside

August 2017 : Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors

July 2017 : Insights from Genome-Wide Association Analyses of Nonalcoholic Fatty Liver Disease

SOME NASHBIOTECHS POINTS OF VIEW RELATED WITH SEMAGLUTIDE


WWW.NASHBIOTECHS.COM  -  Copyright G DIVRY 2015-2016  - Contact and TERMS OF USE